Advertisement

Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Bayer AG. (7/21/17). "Press Release: Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma [Not intended for U.S. and UK Media]". Berlin.

Organisations Organisation Bayer AG
  Group Bayer (Group)
  Organisation 2 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
  Group MorphoSys (Group)
Products Product anetumab ravtansine (BAY 94-9343)
  Product 2 clinical research
Index term Index term Bayer–MorphoSys: HuCAL®, 200512– 5y extension HuCAL GOLD® antibody library access for Bayer Pharmaceuticals Corp w up to 25 new antibody programs
Person Person LaCaze, Robert (Bayer 201702– EVP of new Oncology Strategic Business Unit joined 2015 from BMS)
     


   
Record changed: 2017-07-26

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px

More documents for Bayer (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px




» top